---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-24-000007"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T13:10:53.407639+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kiora licenses KIO-301 to Théa for up to $301M; $16M upfront, milestones, royalties

## Summary
- $16M upfront; up to $285M in milestones and tiered royalties up to low 20% on net sales.
- TOI gets exclusive worldwide rights (ex-Asia) for retinitis pigmentosa and other ophthalmic uses.
- Kiora responsible for Phase 2 design; TOI for Phase 3 and commercialization.
- Phase 1/2 ABACUS data showed meaningful vision improvements; Phase 2 starts early 2024.
- Investor webcast scheduled for Jan 31, 2024 at 5:30 pm ET.

## SEC filing metadata
- accession: 0001372514-24-000007
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000007/0001372514-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000007/kprx-20240125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-24-000007
- JSON: https://secwatch.observer/filing/0001372514-24-000007.json
- Plain text: https://secwatch.observer/filing/0001372514-24-000007.txt

## Key facts
- Material Agreements
  KIORA PHARMACEUTICALS INC entered into Exclusive License and Development Agreement with Théa Open Innovation SAS valued at up-front payment of $16.0 million (effective 2024-01-25).
  - Action: entry
  - Agreement: license
  - Counterparty: Théa Open Innovation SAS
  - Value: up-front payment of $16.0 million
  - Effective: 2024-01-25
  source text: On January 25, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Exclusive License and Development Agreement (the “Agreement”) with Théa Open Innovation SAS (“TOI”) with respect to the Company’s KIO-301 molecular photoswitch product (the “Product”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000007/0001372514-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.